Rentschler Biopharma SE

What Rentschler Biopharma SE does

Rentschler Biopharma SE is a German family-owned contract development and manufacturing organization (CDMO) headquartered in Laupheim, Germany, specializing in bioprocess development and cGMP manufacturing of complex biopharmaceuticals for clinical and commercial supply. Founded in 1875, the company has operated as a biopharma CDMO since the early 1970s and is controlled by the Rentschler family, with Prof. Dr. Nikolaus F. Rentschler serving as Chairman of the Supervisory Board. It serves enterprise biopharmaceutical customers across multiple therapeutic areas including oncology, hematology, musculoskeletal, cardiovascular, and organ failure indications, and reports contributing to nearly 25% of FDA-approved biopharmaceuticals in 2023 across 180+ clients.

The company operates an eight-service platform comprising Analytical Development, Process Development, cGMP Manufacturing, Formulation Development, integrated Development Services, Xpert Alliance fill-finish, Client Program Management, and Regulatory Affairs Consulting. Manufacturing infrastructure includes 3,000L stainless steel bioreactors at Laupheim and four 2,000L single-use bioreactors at the Milford, MA facility, which was acquired in 2019 and expanded with a new production line that came online in 2024, effectively doubling global cGMP capacity. Approximately 1,400 employees work across the German and U.S. sites, and the company holds ISO/IEC 27001:2022 certification for information security at Laupheim alongside cGMP compliance and an Ecovadis Silver sustainability rating.

Rentschler generates revenue through long-term contract manufacturing and development agreements priced on a quote-based, project-by-project basis; pricing is not publicly disclosed. Distribution is direct enterprise sales via a dedicated Business Development Team, supplemented by trade fair presence, expert insights publications, and corporate social channels. The customer base is exclusively enterprise biopharma clients reached globally, with strategic emphasis on serving both U.S. and EU markets through dual-site operations. Recent strategic actions include a December 2025 collaboration with Coriolis Pharma to integrate formulation and analytical services, and a Laupheim buffer media station under construction, targeted to be operational by 2028.

Name

Rentschler Biopharma SE

Legal name

Rentschler Biopharma SE

Website

https://rentschler-biopharma.com

Company type

Private

Founded year

1875

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Rentschler Biopharma SE is a family-owned German CDMO providing full-service bioprocess development and cGMP manufacturing of complex biopharmaceuticals for enterprise biopharma clients across the U.S. and EU from its Laupheim and Milford, MA sites.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)

Keywords

• Biopharmaceutical contract manufacturing
• CGMP bioprocess development
• Biologics manufacturing services
• Analytical method development
• Fill finish services

Headquarters

HQ city

Laupheim

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: Rentschler Biopharma operates as a CDMO providing bioprocess development, cGMP manufacturing, analytical services, and regulatory consulting to biopharmaceutical companies. Revenue is generated through long-term contracts for clinical and commercial drug substance manufacturing, with services spanning from early development through commercial production.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Rentschler Biopharma SE is a global full-service Contract Development and Manufacturing Organization (CDMO) that provides bioprocess development, cGMP-compliant clinical and commercial manufacturing, analytical method development, formulation development, fill-finish services (via the Xpert Alliance), regulatory affairs consulting, and client program management for biopharmaceutical companies. The company operates from facilities in Laupheim, Germany and Milford, Massachusetts, serving international biopharma clients developing complex therapeutics including those for oncology, hematology, musculoskeletal, cardiovascular, and organ failure indications.

Product overview

Rentschler Biopharma SE operates as a global Contract Development and Manufacturing Organization (CDMO) offering an integrated, full-service platform for biopharmaceutical development and manufacturing. The company's portfolio consists of eight core service modules that work together to support clients from early concept through commercial market launch. The service ecosystem includes: Analytical Development (method development and validation), Process Development (bioprocess optimization), cGMP Manufacturing (clinical and commercial production), Formulation Development (drug product optimization), Development Services (integrated lifecycle support), Xpert Alliance for Fill & Finish operations, Client Program Management (project coordination), and Regulatory Affairs Consulting. This platform-plus-services architecture enables clients to access comprehensive biopharmaceutical manufacturing capabilities through a single CDMO partner, with facilities in Laupheim, Germany and Milford, Massachusetts, USA.

Differentiator

Problem solved

Functional benefit

Products and services

• Analytical Development Comprehensive analytical method development, establishment, qualification, validation, and transfer services following cGMP guidelines, supporting product quality, identity, purity, and efficacy throughout clinical phases to commercial manufacturing for biopharmaceutical clients.
• Process Development Bioprocess development services for designing and optimizing manufacturing processes for biopharmaceutical production, ensuring scalable and efficient workflows from early development through commercial scale-up.
• cGMP Manufacturing Good Manufacturing Practice (cGMP) compliant manufacturing for clinical and commercial supply of biopharmaceuticals, offering large-scale production capabilities with bioreactors up to 3,000 liters and multi-product facility flexibility at Laupheim (Germany) and Milford (USA) sites.
• Formulation Development Formulation development services for optimizing drug product compositions, stability, and delivery characteristics to ensure product efficacy and patient acceptability for biopharmaceutical clients.
• Development Services Integrated development services supporting the entire biopharmaceutical product lifecycle from early-stage research through clinical trial material production and commercial launch preparation.
• Xpert Alliance Fill & Finish Fill-finish manufacturing services through the Xpert Alliance partnership with Leukocare, providing automated vial filling and final product manufacturing capabilities for injectable biopharmaceuticals, integrating formulation expertise with bioprocess development and manufacturing.
• Client Program Management Comprehensive project management services coordinating all aspects of biopharmaceutical development and manufacturing programs, ensuring seamless communication and timeline adherence across project phases for client programs.
• Regulatory Affairs Consulting Regulatory affairs consulting services assisting with international regulatory submissions, compliance documentation, and strategic guidance for navigating FDA, EMA, and other global regulatory requirements for biopharmaceutical products.

Quantifiable outcome

• Contribution to nearly 25% of FDA-approved biopharmaceuticals in 2023
• +2 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Coriolis PharmacoreStrategic or Co-development Partner · 1 December 2025Strategic collaboration to offer integrated biopharmaceutical solutions, combining Rentschler Biopharma's bioprocess development and manufacturing expertise with Coriolis Pharma's formulation and analytical capabilities. The partnership provides clients a unified interface from early development through commercial manufacturing, aiming to reduce tech transfer risks and accelerate product timelines. The integrated service offering became available starting December 2025, with both organizations operating in Germany and the United States.
• LeukocarecoreStrategic or Co-development PartnerXpert Alliance partnership for fill-finish services, providing clients with integrated drug product development and manufacturing capabilities. The alliance combines formulation expertise with bioprocess development and manufacturing.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Lonza Group: Global leader in biologics CDMO services including mammalian cell culture, microbial fermentation, and fill-finish. Closely comparable to Rentschler as a full-service biopharmaceutical CDMO serving large and small biopharma clients, though Lonza is significantly larger and publicly listed.
• Boehringer Ingelheim BioXcellence: Biologics CDMO arm of Boehringer Ingelheim offering mammalian cell culture contract manufacturing from process development through commercial supply. Directly comparable to Rentschler in scope (mAbs/recombinant proteins CDMO) and serves the same enterprise biopharma clients.
• Samsung Biologics: Korean-based biologics CDMO operating the world's largest single-site mammalian cell culture capacity (including 15,000L bioreactors). Provides contract manufacturing services from clinical to commercial scale, directly competing for large commercial biologics programs.
• WuXi Biologics: China-headquartered global biologics CDMO offering end-to-end services from cell line development through commercial manufacturing. Comparable full-service platform with global footprint; one of the largest biologics CDMOs by capacity.
• Catalent (Novo Holdings): Global CDMO with biologics, fill-finish, and drug product capabilities. Acquired by Novo Holdings in 2024. Directly comparable CDMO peer serving similar biopharma customers, though with broader modalities including cell and gene therapy.
• Fujifilm Diosynth Biotechnologies: Global biologics CDMO with facilities in the US, UK, and Denmark offering mammalian and microbial contract manufacturing. Direct competitor in mammalian cell culture CDMO with comparable process development and cGMP manufacturing services.
• AGC Biologics: Global CDMO focused on biologics (mammalian and microbial) and cell/gene therapy. Comparable in offering full-service biologics contract development and manufacturing to mid- and large-cap biopharma clients across clinical and commercial stages.
• Vetter Pharma: German family-owned CDMO specializing in aseptic fill-finish and final assembly of injectable biologics. Similar family-owned German heritage and biologics focus; comparable in serving enterprise biopharma clients with complex manufacturing needs, though Vetter specializes more in fill-finish rather than drug substance.

Broad incumbents

• Thermo Fisher Scientific (Patheon/CDMO services): Global life sciences conglomerate with substantial CDMO operations including biologics manufacturing through its Pharma Services segment. Comparable CDMO services but as part of a much broader portfolio (instruments, reagents, diagnostics, clinical research).
• Recipharm: European CDMO offering biologics fill-finish and small molecule manufacturing services. Comparable CDMO model serving global biopharma clients, though Recipharm has a broader small-molecule focus and is more of a broad incumbent than a pure-play biologics CDMO.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/2408523
• YouTubeyoutube.com/RentschlerBiopharma

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rentschler Biopharma SE